AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02169791
Drug: MLN9708
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLN9708 will be given weekly x 3 weeks every 28 day cycles, for up to 12 cycles starting at D+5 post-transplant.
Trial: NCT00291473
Drug: CHP-HER2, CHP-NY-ESO-1
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02466386
Drug: SPD489
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 5 mg of SPD489 capsule orally once daily in the morning and titrated in a step-wise fashion up to either 10 mg, 15 mg, 20 mg, or 30 mg until an optimal dose was reached.
Trial: NCT01966809
Drug: Photofrin photodynamic therapy.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will receive a dose of 2.5 mg/kg of Photofrin intravenously 24 hours before planned surgical resection. Tumor resection will be carried out in the standard fashion in order to achieve the maximum tumor resection compatible with preservation of neurological function. After resection, Intralipid will be infused into the craniotomy and kept for approximately 45 min, while PDT will be performed. The illumination time will be calculated from the power density (mW) emitted by the laser and the radius (r) of the cavity to deliver a total light dose of 240 J/cm2 at a using the following formula:~Treatment Time (sec) = Light dose (J/cm2) x Cavity surface (cm2) x 1000 Power density (mW) Cavity Surface (cm2) = 4 x 3.14 x r2 The optical fiber will be placed in the center of the surgical cavity and photoillumination will commence. After PDT, the Intralipid solution will be removed and the wound will be closed. The subject will be sent to the intensive care area for recovery.
Trial: NCT00779220
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous repeating dose
Trial: NCT00779220
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral repeating dose
Trial: NCT01083238
Drug: AZD5069
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120mg single oral dose
Trial: NCT00980408
Drug: Glutamic Acid
RxNorm normalized name: Glutamic Acid
DrugBank: Glutamic acid (DB00142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250 mg, one dose, 60 minutes prior
Trial: NCT00136760
Drug: Contingent reinforcement plus placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: contingent reinforcement plus placebo (3 weeks)
Trial: NCT00136760
Drug: Non-contingent reinforcement plus placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-contingent reinforcement plus placebo
Trial: NCT01634412
Drug: SL TNX-102 2.4 mg at pH 3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of 2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 3.5, administered as 1 mL held under the tongue for 90 seconds without swallowing
Trial: NCT01634412
Drug: SL TNX-102 2.4 mg at pH 7.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of 2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 7.1, administered as 1 mL held under the tongue for 90 seconds without swallowing
Trial: NCT00159536
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 2 tablets x 2 daily.Orally. From inclusion (that is before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study
Trial: NCT02635035
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo looks just like Vyvanse but has no active ingredients, like a sugar pill.
Trial: NCT00869440
Drug: CNS 7056
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as a single intravenous injection by a syringe driver over 1 minute
Trial: NCT04314843
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered according to package insert
Trial: NCT02111122
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00004344
Drug: testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00267163
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02586363
Drug: Baraclude Tab. 0.5mg, fasting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)
Trial: NCT02586363
Drug: Cavir Tab. 0.5mg, fasting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)
Trial: NCT02586363
Drug: Cavir Tab. 0.5mg, high fatty meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)
Trial: NCT01886937
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food intake as measured by a laboratory study should be greater after 7 days of placebo administration compared to seven days of phentermine administration.
Trial: NCT01795235
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar Pill
Trial: NCT03649698
Drug: Placebo protein powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocaloric maltodextrin powder. Amount based on food diary.
Trial: NCT03649698
Drug: Placebo omega-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peanut oil soft gel capsules. 1g/ capsule. 1 capsule/day
Trial: NCT00039910
Drug: (PN-152,243)/ PN-196,444
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00537017
Drug: Other Parkinson's Disease treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants may also receive other drugs as part of their usual ongoing treatment for Parkinson's Disease, such as dopamine agonists (e.g., pramipexole) and/or the catechol-O methyl transferase (COMT) inhibitor entacapone.
Trial: NCT00145613
Drug: Systemic chemotherapy and antibodies
RxNorm normalized name: Estradiol and Levonorgestrel Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transplant recipients received a non-TBI based reduced intensity conditioning regimen consisting of OKT-3, Fludarabine Thiotepa, and Melphalan. Rituximab was administered within 24 hours of the transplant in an effort to prevent PTLPD. In addition to T-cell depletion of the haploidentical stem cell product, Mycophenolate mofetil was provided as prophylaxis for GVHD.
Trial: NCT00406016
Drug: ATI355
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00635960
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same as for Growth hormone group
Trial: NCT01923311
Drug: Background regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Background regimen may consist of the following ritonavir (RTV)-boosted PIs (PI/r): lopinavir/r (Kaletra), atazanavir/r, darunavir/r, tipranavir/r, or fosamprenavir/r. For participants \< 2 months old, only lopinavir/r is allowed. Use of additional antiretrovirals in background therapy may be allowed.
Trial: NCT04119557
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT04119557
Drug: LY3471851
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT00772616
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: closed-loop administration using bispectral index as the single input for the controller.
Trial: NCT00772616
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dosage according to usual criteria
Trial: NCT00757679
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules
Trial: NCT00578968
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to this arm received a once daily oral inhalation of placebo powder to match the standard active comparator dose, using the HandiHaler device.
Trial: NCT00332124
Drug: Choline
RxNorm normalized name: Choline
DrugBank: Choline (DB00122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 900 mg every day until birth of infant
Trial: NCT02234089
Drug: LHRH agonist (Leuprorelinacetat, Goserelinacetat, Buserelinacetat, Triptorelinacetat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to medical practice
Trial: NCT03471988
Drug: AK1820
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only a switch from IV infusion (vial) to oral administration (capsule) will be permitted; a switch from oral administration to IV infusion will not be possible.~372.6 mg of AK1820 (isavuconazonium sulfate) is equivalent to 200 mg of isavuconazole.~Other Names: Cresemba, BAL8557
Trial: NCT03081728
Drug: IV diclofenac and IV paracetamol
RxNorm normalized name: codeine and paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv diclofenac 75 mg TDS iv paracetamol 1gm TDS
Trial: NCT01636934
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg by mouth two times a day (200 mg/day) every day for 7 weeks, starting on the first week of chemoradiation therapy.
Trial: NCT00159835
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02733627
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02688387
Drug: FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The four FDCs in part 1 will have the following formulation designation: FDC1, FDC2, FDC3 and FDC4. They are film-coated tablets. The dose will be administered orally. Study treatment for Part2 and Part 3 will be amended after Part 1 study
Trial: NCT03055741
Drug: DHP1401
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total 500mg or 1,000mg was administrated in two divided doses a day for 24 weeks
Trial: NCT03055741
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was administrated in two divided dosed a day for 24 weeks
Trial: NCT02448420
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-steroidal AIs (anastrozole, letrozole); steroidal AI (exemestane); Fulvestrant or Tamoxifen
Trial: NCT02448420
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine, vinorelbine, capecitabine, eribulin or a taxane
Trial: NCT02959944
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules administered orally daily
Trial: NCT00546910
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 capsules of placebo have to be taken once daily in the morning, with or without food.
Trial: NCT03164109
Drug: GC4419 IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg infused IV over 15 minutes
Trial: NCT03164109
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infused IV over 15 minutes
Trial: NCT00399893
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to be administered by subcutaneous injection three times daily while on study
Trial: NCT04412057
Drug: CERC-002
RxNorm normalized name: CERCIS SILIQUASTRUM WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered once subcutaneously at 16 mg/kg dose up to a maximum dose of 1200 mg.
Trial: NCT04412057
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered once subcutaneously
Trial: NCT01529268
Drug: DR cysteamine bitartrate capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline~* 750 mg/day (five 75 mg capsules twice daily) for patients \>65 - 80 kg at baseline~* 900 mg/day (six 75 mg capsules twice daily) for patients \>80 kg at baseline
Trial: NCT01158326
Drug: Resfenol
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (acetaminophen), chlorpheniramine maleate, phenylephrine hydrochloride.~10 ml of oral solution acetaminophen, chlorpheniramine maleate, phenylephrine hydrochloride every 6 hours for 48 hours.
Trial: NCT03747653
Drug: FRSW107
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be administered a single dose of FRSW107 for Injection.
Trial: NCT02801435
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration for twice daily
Trial: NCT00493064
Drug: Prednisolone acetate
RxNorm normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: topical eye drops
Trial: NCT02037282
Drug: Anti-influenza IVIG
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06267794
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg dosage. Additionally, all participating subjects will receive standard treatment care for patients with cirrhosis.
Trial: NCT04082806
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo oral solution (placebo for GHB) and placebo pills (placebo for trazodon)
Trial: NCT03446599
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200ml normal saline will be administered intravenously over 10-15minutes at the time of initiation of cardiopulmonary bypass.
Trial: NCT02833207
Drug: Drug Trial 1 (EDD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs that increase blood flow and test EDD are: ACh, ISO, BK, ATP. Remaining drugs used to test mechanisms of EDD: L-NMMA, ketorolac, and BaCl2.~Details under study description.
Trial: NCT02833207
Drug: Drug Trial 2 (ROV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tools used to increase blood flow: muscle contractions and ATP. Remaining drugs used to test mechanisms of ROV: L-NMMA, ketorolac, and BaCl2.~Details under study description.
Trial: NCT03355196
Drug: LRX712
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascending single dose on Day 1
Trial: NCT02135198
Drug: 2 mg AZD7325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single 2 mg oral dose of AZD7325
Trial: NCT02135198
Drug: 10 mg AZD7325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single 10 mg oral dose of AZD7325
Trial: NCT03355196
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascending single dose on Day 1
Trial: NCT02135198
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose
Trial: NCT00504933
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (encapsulated) Tablets QD/14 days
Trial: NCT01098110
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A matching placebo of asenapine sublingual tablet not containing asenapine
Trial: NCT02147587
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets twice daily with background methotrexate for 12 weeks
Trial: NCT02184741
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects received the same dose of saline as GB-0998 for 5 days after confirmation of the gestational sac by ultrasonography, up to 6 weeks and 6 days of gestation.
Trial: NCT02330952
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mg/day per os for 5 days
Trial: NCT02270749
Drug: FitForMe vitamin B12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients are treated for 6 months with a daily dose of 1000ug vitamin B12 tablets. At timepoint 0, 2, 4 and 6 months after treatment vitamin B12 will be measured. At timepoint 0 and 6 also homocystein and methylmalonic acid will be measured.
Trial: NCT02786927
Drug: Placebo ELLIPTA device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ELLIPTA is a DPI device containing powder for inhalation, to be inhaled orally once daily for 5-9 days. It contains two strips with 30 blisters per strip - one strip contains lactose monohydrate whereas the other strip contains lactose monohydrate blended with magnesium stearate.
Trial: NCT02786927
Drug: Placebo capsules for use in HANDIHALER device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules contain lactose monohydrate in the form of powder for inhalation, to be used with the HANDIHALER inhaler as an oral inhalation once daily for 5-9 days.
Trial: NCT00974454
Drug: Fuzheng 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunity 2 (Fuzheng 2), 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Trial: NCT03749733
Drug: Estradiol 1.5 mg/nomegestrol acetate 2.5 mg (Reference Product)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marketed Drug
Trial: NCT03749733
Drug: Estradiol 1.5 mg/nomegestrol acetate 2.5 mg (Test Product)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational Medicinal Product
Trial: NCT03327350
Drug: Oral anticoagulant drugs
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group will take oral anticoagulant drugs(warfarin or the new oral anticoagulant drugs like Dabigatran ).For patients taking warfarin,international normalizedratio (INR) monitoring wil be performed at least every 2 weeks for 6 months and at least monthly thereafter, targeting an INR between 2 and 3. Followup visits occurred twice annually after the first year,with neurological assessments at 12 months and yearly thereafter or whenever a neurological event is suspected.
Trial: NCT03019562
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50ug of fentanyl iv 20 min before the end of surgery, 10ug/kg of fentanyl in Patient-Controlled Analgesia(PCA),
Trial: NCT00974454
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Trial: NCT01350596
Drug: Alivium®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg of Ibuprofen equivalent to 8mL (50mg/mL) oral suspension of the Reference Drug
Trial: NCT01350596
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400mg of Ibuprofen equivalent to 8mL (50mg/mL) oral suspension of the Test Drug
Trial: NCT00914212
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose placebo to sibutramine in two of three treatment periods.
Trial: NCT03879122
Drug: ADT (androgen deprivation therapy)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy per the standard of care
Trial: NCT01923220
Drug: HO/02/02 20µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interventions involving HO/02/02 20µg VS. Aloe Vera Jel (SOC). Treatment will be applied topically once daily
Trial: NCT02466334
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 ml of normal saline over 20 mins
Trial: NCT00206596
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily via subcutaneous injection for up 22 weeks
Trial: NCT03046082
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation of antibiotic types given to patients with pneumonia.
Trial: NCT01265667
Drug: CF101
RxNorm normalized name: CF101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally q12h
Trial: NCT01265667
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally q12h
Trial: NCT01705002
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg dose BID PO for days 1-21 for Combination Cohort and on day 1-14 on Triple combination Cohort
Trial: NCT02630316
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered four times daily
Trial: NCT00585312
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: celecoxib, 16 mg/kg/day, for 5 years
Trial: NCT00585312
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Masked, placebo comparator
Trial: NCT00964106
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine dosed at 100 mg as probe for CYP1A2 pathway
Trial: NCT00964106
Drug: Flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosed at 40 mg, probe for CYP2C9 pathway
Trial: NCT00964106
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dosed at 10 mg, probe drug for OATP1B1 pathway
Trial: NCT03045822
Drug: Bioimpedance analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00575380
Drug: Vigamox Eye Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop three times a day for seven days
Trial: NCT00931996
Drug: Antipsychotic
RxNorm normalized name: ANTIPSYCHOTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone is the first line antipsychotic followed by others per clinician choice. Flexible dosing QD x 4-6 weeks.
Trial: NCT00384306
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no